drugset / Trial / NCT04864418
AST-021p Study in Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors A phase 1 study
Timeline
- Start
- 2021-06-09
- Primary completion
- 2023-08
- Completion
- 2023-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AST-021p | Vaccine | 1.2 mg | — |
| Subject | AST-021p | Vaccine | 2.4 mg | — |
| Subject | AST-021p | Vaccine | 3.6 mg | — |
| Subject | AST-021p | Vaccine | 4.8 mg | — |